Delivery Order HHSN261201600018I-75N91018F00002

This is a $249,167.58 firm fixed price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Gempharmatech LLC, a foreign-owned for-profit biotech company. The contract is for the development of humanized mouse models for nicotinamide N-methyltransferase (NNMT) and sulfotransferase (SULT1A1) using CRISPR knock-in technology. The contractor will conduct biochemical testing of inhibitors and...

The U.S. Department of Health and Human Services, National Institutes of Health, National Center for Advancing Translational Sciences awarded a firm-fixed price delivery order contract to A&G Pharmaceutical, Inc., doing business as Precision Antibody, to generate drug-specific monoclonal antibodies against TTHX1114, an engineered mutant human FGF1. The $50,208.55 contract has a completion date of June 30, 2020 and does not have a set-aside designation. Precision Antibody is a for-profit...

This firm fixed-price purchase order was awarded by the Department of Health and Human Services Food and Drug Administration to Genoway, a global biotechnology company, to provide services related to the revitalization, shipment, and establishment of replacement embryos for the YAN1 and YAN2 mouse lines. The potential value of the contract is $22,800.00, and it has a completion date of August 9, 2022. Genoway has previously provided similar services to the DHHS FDA, including the development...

This is a firm fixed-price federal contract award from the Veterans Integrated Service Network 12, a civilian agency, to Gempharmatech LLC, a foreign-owned for-profit biotechnology company. The contract is for the generation of PGP/MDR1A floxed live mice, a specialized mouse model, to support preclinical drug discovery and development research. The contract has a ceiling value of $13,509.55 and a completion date of March 14, 2025. Gempharmatech has previously received similar contract awards...

This is a 2-year, firm fixed price (FFP) type task order awarded to Core Human Factors, Inc. by the Food and Drug Administration (FDA), a civilian agency. The contract is to procure comparative use human factors (CUHF) studies to assess the impact of differences between the user interfaces of a generic drug-device combination product and its reference listed drug. The contract has a ceiling value of $679,960.00 and does not have a set-aside designation. The award date is September 18, 2024,...

This is a new task order awarded by the Food and Drug Administration (FDA) to Biopharma Services USA, Inc. under an existing contract (HHSF223201610004I) to perform a study titled "Evaluation of Formulation Dependence of Drug Interaction with Proton Pump Inhibitors (PPIs)." The task order is for an in vivo study of generic drug products in human subjects and has a not-to-exceed ceiling value of $1,320,689.00. The contract is a firm fixed price Delivery Order with a period of...

This is a firm fixed price purchase order awarded by the National Institute of Child Health and Human Development (NICHD), a civilian agency within the U.S. Department of Health and Human Services, to Gempharmatech LLC, a foreign-owned for-profit biotechnology company. The contract is for the development of a conditional knockout mouse line to support NICHD's research. The total ceiling value of the contract is $14,380.00 with a completion date of January 5, 2024. There is no set-aside...

This is a firm fixed price purchase order contract awarded by the National Institute on Aging (NIA), a civilian agency within the National Institutes of Health (NIH), to Gempharmatech LLC, a foreign-owned for-profit biotechnology company. The contract is for the delivery of specialized Kremen1-flox mice, which are a type of knockout mouse model, to support preclinical drug discovery and development research. The contract has a ceiling value of $13,509.55 and a completion date of November 19,...

This is a federal contract award to Southern Research Institute, a non-profit organization, by the National Cancer Institute (NCI) of the National Institutes of Health (NIH), Department of Health and Human Services (HHS). The 12-month contract, with a potential value of $358,997.00, is for a toxicology study of the human complement factor H antibody GT103 in mice. The contract is a Delivery Order under the parent "Toxicology of Drugs Developed for Cancer Patients" IDIQ contract...

Chemogenics Biopharma, LLC has been awarded a $23,540 firm fixed price purchase order by the National Institutes of Health's National Center for Advancing Translational Sciences to evaluate the pharmacokinetics of aldometanib in mice. Under the non-competitive contract, Chemogenics will determine aldometanib concentrations in various tissues through synthesis of the compound following a multistep sequence and analytical methods to analyze aldometanib levels. The company will also report and...